Forum

Dear Guests,

Welcome to ICOASE 2018!

You can use this forum for any discussions for the ICOASE 2018. You can create topics or answer questions either if you are registered or as a guest (without registration).

If you want you can create a new topic if such a topic does not exist (Not discussed before), or reply to any topic if you have a reasonable answer so that others can get your idea.

Feel free to ask any question and in any language!

Thanks for your cooperation.


Vaccine Research and Development CRO in Pakistan

Quote

Communicable diseases Infectious Disease CRO in Southeast Asia a major concern for public health worldwide. Health issues like hepatitis, HIV, tuberculosis, dengue, influenza, and emerging viral infections impact global populations every year. To combat these diseases, robust clinical research and effective vaccines and antiviral treatments are essential.

Infectious Disease CROs play a key role in supporting pharmaceutical and biotechnology companies across Phase I to Phase IV studies. In recent years, the Asia-Pacific region has emerged as a leading destination for infectious disease studies.

Clinical Research for Infectious Diseases in Southeast Asia

Southeast Asia offers unique advantages for vaccine and hepatitis trials, including:

Access to treatment-naïve populations

High prevalence of infectious diseases

Experienced investigators and research sites

Efficient operational costs

Improving regulatory frameworks

Countries such as Indonesia, Malaysia, the Philippines, Thailand, and Pakistan are frequently chosen for viral disease research.

Infectious Disease CRO in Indonesia

Indonesia is a major contributor for vaccine research due to its large population. Significant disease burden allows for efficient enrollment.

It is particularly suitable for late-phase vaccine trials.

Malaysia Infectious Disease CRO Services

The Malaysian clinical research environment is known for its strong research ecosystem. Key strengths include strong compliance frameworks, reliable monitoring practices, and excellent patient retention.

Malaysia is well positioned for infectious disease research programs.

Philippines Infectious Disease Clinical Trials

The Philippines has become a preferred destination for international studies. Advantages include high patient compliance, competitive trial timelines, and strong experience in vaccine studies.

Infectious Disease CRO in Thailand

This region has a global recognition in infectious disease research. The country offers internationally accredited hospitals and plays a critical role in early- and late-phase infectious disease trials.

Pakistan Infectious Disease Clinical Research

This country presents unique opportunities for infectious disease research. With a diverse demographics, Pakistan enables efficient enrollment.

Tigermed Infectious Diseases Expertise

This global CRO is a leading international CRO with extensive experience in global infectious disease programs.

Tigermed provides comprehensive CRO solutions, including:

Study planning and feasibility assessment

Global and regional regulatory support

Investigator management

Data collection and quality control

Pharmacovigilance and safety reporting

Biostatistics and medical writing

By combining regional knowledge with ICH-GCP compliance, Tigermed enables efficient, compliant, and high-quality infectious disease trials.

Final Thoughts

The global rise in viral infections underscores the need for strong CRO partnerships. Asia-Pacific regions offer significant potential for infectious disease research.

Partnering with an trusted clinical research organization ensures scientific excellence and supports the future of global public health.


If you want to register to the website so that your name is visible to others, please follow the following steps:

  1. Click on the register
  2. Enter a valid email to be registered with
  3. Check your entered email to verify your email address and set a new password for you
  4. Goto Forum and log-in with your email and password
  5. Ask your question to the forum

Kind regards,